Tris Pharma, Inc.
Tris Pharma, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has established itself as a pioneer in developing innovative drug delivery systems, particularly in the areas of paediatrics and chronic pain management. Tris Pharma focuses on creating unique formulations that enhance patient compliance and therapeutic outcomes, setting it apart from competitors. With a strong presence in the US market, Tris Pharma has achieved significant milestones, including the successful launch of several proprietary products that address unmet medical needs. The company’s commitment to research and development, coupled with its expertise in complex formulations, has solidified its position as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Tris Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tris Pharma, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tris Pharma, Inc.'s reported carbon emissions
Tris Pharma, Inc., headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes initiatives aimed at reducing greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As the industry evolves, Tris Pharma may adopt similar strategies to enhance its environmental responsibility and address climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tris Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
